Dr. Harminder S. Sethi

Dennis Priebat is a Hematologist Oncology specialist and an Oncologist in Washington, Washington, D.c.. Dr. Priebat is rated as a Distinguished provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Mesenchymoma, and Rhabdomyosarcoma Embryonal.

Dr. Meyer will serve as the lead medical oncologist for adult sarcoma patients, and will focus on building the Adult Sarcoma and Connective Tissue Oncology Program. In collaboration with pediatric oncologist David Loeb, M.D., Ph.D., and orthopaedic surgeon Kristy Weber, M.D., Meyer will bring novel therapies to the clinic for sarcoma patients. Meyer received his bachelors and masters degrees in cell and molecular biology from Stanford University. From there, he joined the Medical Scientist Training Program at Baylor College of Medicine and earned his medical degree followed by a doctorate in immunology. Meyer completed his residency at the University of Maryland and served as chief resident in medicine from 2004-2005. Afterward, he joined our fellowship program in medical oncology and has been working in the laboratory of Jonathan Powell, M.D., Ph.D., on projects relating to the characterization of molecular regulatory pathways involved in T-cell activation and energy. As a third-year fellow, Meyer served as the chief fellow for our Training Programs in Hematology and Medical Oncology and he received a Young Investigator Award from the American Society of Clinical Oncology in 2010. Dr. Meyer is rated as a Distinguished provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Mesenchymoma, Undifferentiated Pleomorphic Sarcoma, Bone Tumor, and Ganglioneuroblastoma.

Karim Boudadi, M.D., is a medical oncologist and hematologist with the Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital in Washington, D.C., and an assistant professor in the Department of Oncology at Johns Hopkins University School of Medicine. Listen to Dr. Boudadi’s Cancer Matters podcast episode to learn more about his work. Dr. Boudadi has expertise in treating cancers of the head and neck, including salivary gland cancers, as well as cancers of the esophagus, and bone and soft tissue sarcomas. Having completed dual training in medical oncology and hematology at Johns Hopkins University, Dr. Boudadi also treats patients with benign hematologic conditions or non-cancer related blood disorders, such as anemia, low blood counts, bleeding disorders, and clotting disorders. Dr. Boudadi earned his medical degree from the University of Rochester School of Medicine. He completed a residency in internal medicine at the University of Michigan in Ann Arbor, MI, and went on to serve as a clinical lecturer in the Department of Internal Medicine at the University of Michigan Medical School before joining Johns Hopkins. He then completed dual fellowship training in both hematology and medical oncology at the Johns Hopkins University School of Medicine. Dr. Boudadi's research during his fellowship focused on prostate cancer and immunotherapy. Dr. Boudadi is a member of the American Society of Clinical Oncology, the American Society of Hematology, the American College of Physicians, and the American Medical Association. He is also a member of the Hematology and Oncology Fellowship Selection Committee at The Johns Hopkins University School of Medicine. Dr. Boudadi has extensive clinical trial development experience and has published his work in peer-reviewed journals. His primary research interest is immunotherapy. Recent News Articles and Media Coverage Cancer Matters Podcast: Dr. Bill Nelson discussing the treatment of HPV related head and neck cancers, Johns Hopkins Kimmel Cancer Center Podcasts (May 23, 2019). Dr. Boudadi is rated as an Advanced provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Glioma, Mesenchymoma, Undifferentiated Pleomorphic Sarcoma, Gastrointestinal Stromal Tumor, and Prostatectomy.